Aware Super Pty Ltd as trustee of Aware Super Takes $5.18 Million Position in Cencora, Inc. $COR

Aware Super Pty Ltd as trustee of Aware Super purchased a new stake in shares of Cencora, Inc. (NYSE:COR) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 16,494 shares of the company’s stock, valued at approximately $5,181,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Cencora by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock valued at $7,976,681,000 after acquiring an additional 221,570 shares during the period. State Street Corp boosted its holdings in shares of Cencora by 1.3% in the fourth quarter. State Street Corp now owns 9,305,507 shares of the company’s stock worth $3,142,935,000 after acquiring an additional 115,191 shares during the period. T. Rowe Price Investment Management Inc. grew its position in shares of Cencora by 160.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after purchasing an additional 4,123,795 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Cencora by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock valued at $1,843,268,000 after purchasing an additional 169,055 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Cencora by 6.5% during the 4th quarter. JPMorgan Chase & Co. now owns 4,982,557 shares of the company’s stock valued at $1,682,859,000 after purchasing an additional 304,760 shares during the period. 97.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on COR. William Blair initiated coverage on shares of Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating for the company. Robert W. Baird cut their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Weiss Ratings downgraded shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 30th. Wells Fargo & Company reduced their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Finally, Morgan Stanley set a $342.00 price target on shares of Cencora in a report on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $367.75.

Insider Transactions at Cencora

In other Cencora news, Director Lauren M. Tyler purchased 550 shares of Cencora stock in a transaction that occurred on Monday, June 22nd. The shares were bought at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the acquisition, the director directly owned 4,359 shares in the company, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.38% of the stock is currently owned by corporate insiders.

Cencora Stock Down 0.1%

Shares of NYSE COR opened at $307.72 on Friday. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The firm’s fifty day moving average is $279.98 and its 200 day moving average is $317.68. The company has a market cap of $59.87 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 1.71 and a beta of 0.58.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same period last year, the business earned $4.42 EPS. Cencora’s revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities research analysts expect that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Cencora announced that its board has authorized a stock repurchase plan on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 3.9% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.